Ranjit Banwait
YOU?
Author Swipe
View article: Pilot phase <scp>II</scp> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors
Pilot phase <span>II</span> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors Open
This pilot phase II study evaluated the combination of lenvatinib, a multi‐kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angi…
View article: Data from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
Data from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia Open
Introduction: The serum free light chain (sFLC) has been widely used in the assessment of response in patients with multiple myeloma and other plasma cell dyscrasias. However, its use in Waldenstrom macroglobulinemia (WM) has not been prev…
View article: Supplementary Figure 1 from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Supplementary Figure 1 from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Open
PDF file - 32K, Everolimus targets mTOR-down stream targets in WM patients. Bone marrow specimens have been stained for phosphor(p)-S6R and p-4EBP1. Signal quantification for each target has been obtained from 4 different areas, on matched…
View article: Supplementary Figure Legend from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Supplementary Figure Legend from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Open
PDF file - 38K
View article: Data from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Data from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Open
Purpose: The TORC1 inhibitor everolimus has previously shown significant activity as a single agent in hematologic malignancies, with reported responses of 30% to 70% in Waldenstrom macroglobulinemia. However, the specific mechanisms by wh…
View article: Supplementary Table S1 from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
Supplementary Table S1 from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia Open
Supplementary Table S1 from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
View article: Supplementary Figure Legend from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Supplementary Figure Legend from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Open
PDF file - 38K
View article: Supplementary Figure 1 from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Supplementary Figure 1 from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Open
PDF file - 32K, Everolimus targets mTOR-down stream targets in WM patients. Bone marrow specimens have been stained for phosphor(p)-S6R and p-4EBP1. Signal quantification for each target has been obtained from 4 different areas, on matched…
View article: Data from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
Data from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia Open
Introduction: The serum free light chain (sFLC) has been widely used in the assessment of response in patients with multiple myeloma and other plasma cell dyscrasias. However, its use in Waldenstrom macroglobulinemia (WM) has not been prev…
View article: Data from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Data from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia Open
Purpose: The TORC1 inhibitor everolimus has previously shown significant activity as a single agent in hematologic malignancies, with reported responses of 30% to 70% in Waldenstrom macroglobulinemia. However, the specific mechanisms by wh…
View article: Supplementary Table S1 from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
Supplementary Table S1 from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia Open
Supplementary Table S1 from The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
View article: Prevalence of Hepatopancreatic Injury and Clinical Outcomes in Patients with COVID-19 in United States
Prevalence of Hepatopancreatic Injury and Clinical Outcomes in Patients with COVID-19 in United States Open
Background : 1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. 2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity and length of stay in this cohort.…
View article: Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)
Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19) Open
Taking ACEIs and ARBs prior to admission for COVID-19 was independently associated with decreased need for mechanical ventilation and in-hospital mortality.
View article: Administration of systemic steroids during hospitalization does not improve the clinical outcome in patients with Covid-19
Administration of systemic steroids during hospitalization does not improve the clinical outcome in patients with Covid-19 Open
The systemic steroids are recommended for cases with refractory septic shock or severe acute respiratory distress syndrome.Although systemic glucocorticoids help to resolve inflammation and treat cytokine storm, the time course for steroid…
View article: Thrombocytopenia Associated with Increase in Disease Severity and Mortality in COVID-19 Patients
Thrombocytopenia Associated with Increase in Disease Severity and Mortality in COVID-19 Patients Open
Introduction:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing novel COVID-19 is spreading all across the globe like wildfire. As was the case with severe acute respiratory syndrome coronavirus (SARS) in 2002 and Middle …
View article: Convalescent Plasma in COVID-19
Convalescent Plasma in COVID-19 Open
Description The recent pandemic of SARS-CoV-2, which causes novel coronavirus disease 2019 (Covid-19), has had devastating impact on a global and national scale. In order to overcome this outbreak it is imperative we find treatments that a…